

## REFERENCES

- Whittenberger JL. Artificial respiration. *Physiol Rev.* 1955; 35:611-28.
- Lutkenbenner PP, Rafflenbeul W, Keller H, et al. Application of transtracheal pressure oscillations as a modification of "diffusion respiration." *Br J Anaesth.* 1972; 44:627-8.
- Sjöstrand U. Review of the physiological rationale for and development of high-frequency, positive-pressure ventilation — HFPPV. *Acta Anaesthesiol Scand [Suppl].* 1977; 64:7-27.
- Klaus M, Smith RB. High frequency percutaneous transtracheal jet ventilation. *Crit Care Med.* 1977; 5:280-7.
- Bussell JB, Karlson KH, Shannon DC. High frequency positive pressure ventilation in dogs and rabbits. *Am Rev Respir Dis.* 1978; 117: Suppl.289. abstract.
- Bohn DJ, Miyasaka K, Marchak BE, Thompson WK, Frome AB, Bryan AC. Ventilation by high-frequency oscillation. *J Appl Physiol.* 1980; 48:710-6.
- Butler WJ, Bohn DJ, Bryan AC, Frome AB. Ventilation by high-frequency oscillation in humans. *Anesth Analg (Cleve).* 1980; 59:577-84.
- Carlson GC, Ray C Jr, Klein M, McCormack PM. High-frequency positive pressure ventilation in management of a patient with bronchopulmonary fistula. *Anesthesiology.* 1980; 52:160-2.
- Slutsky AS, Brown R, Lehr J, Roessing TH, Drazen JM. High frequency ventilation: a promising new approach to mechanical ventilation. *Med Instrum.* 1981; 15:229-33.
- Frome AB, Bryan AC. High frequency ventilation. *Am Rev Respir Dis.* 1981; 123:249-50.
- Slutsky AS, Drazen JM, Ingram RH Jr, et al. Effective pulmonary ventilation with small-volume oscillations at high frequency. *Science.* 1980; 209:609-11.
- Slutsky AS, Kamm RD, Roessing TH, et al. Effects of frequency, tidal volume and lung volume on CO<sub>2</sub> elimination in dogs by high frequency (2-30 Hz), low tidal volume ventilation. *J Clin Invest.* (in press).
- Sjöstrand U. Summary of experimental and clinical features of high-frequency positive-pressure ventilation — HFPPV. *Acta Anaesthesiol Scand [Suppl].* 1977; 64:165-78.
- Franz ID, Stark AR, Werthammer J. Improvement in pulmonary interstitial emphysema with high frequency ventilation. *Pediatr Res.* 1981; 15:719. abstract.
- Goldstein DH, Slutsky AS, Ingram RH Jr, Westerman P, Venegas J, Drazen J. CO<sub>2</sub> elimination by high frequency ventilation (4 to 10 Hz) in normal subjects. *Am Rev Respir Dis.* 1981; 123:251-5.
- Custer JR, Shannon DC. High frequency ventilation enhances oxygenation and alveolar ventilation at reduced airway pressures in an animal model of pulmonary edema. *Am Rev Respir Dis.* 1979; 119: Suppl.266. abstract.
- Schmid ER, Knopp TJ, Rehder K. Intrapulmonary gas transport and perfusion during high frequency oscillation. *J Appl Physiol.* (in press).
- Fukuchi Y, Roussos CS, MacIem PT, Engel LA. Convection, diffusion and cardiogenic mixing of inspired gas in the lung: an experimental approach. *Respir Physiol.* 1976; 26:77-90.
- Slutsky AS. Gas mixing by cardiogenic oscillations: a theoretical quantitative analysis. *J Appl Physiol.* (in press).
- Frederberg JJ. Augmented diffusion in the airways can support pulmonary gas exchange. *J Appl Physiol.* 1980; 49:232-8.
- Hasselton FR, Scherer PW. Bronchial bifurcations and respiratory mass transport. *Science.* 1980; 208:69-71.
- Taylor G. Dispersion of soluble matter in solvent flowing slowly through a tube. *Proc R Soc A.* 1953; 219:186-203.
- Idem. The dispersion of matter in turbulent flow through a pipe. *Proc R Soc A.* 1954; 223:446-68.
- Charvat PC. On the longitudinal dispersion of passive contaminant in oscillatory flows in tubes. *J Fluid Mech.* 1975; 71(3):513-27.
- Mead J. Contribution of compliances of airways to frequency-dependent behavior of lungs. *J Appl Physiol.* 1969; 26:670-3.
- Roessing TH, Slutsky AS, Lehr J, et al. The influence of tidal volume (V<sub>T</sub>) on CO<sub>2</sub> output (VCO<sub>2</sub>) during high frequency ventilation (HFV) in dogs. *Am Rev Respir Dis.* 1981; 123(4): Part 2:203. abstract.

## MEDICAL PROGRESS

## CHEMICAL CARCINOGENESIS

EMMANUEL FARBER, M.D., PH.D.

THE perception of cancer as a disease primarily related to the environment has been progressively strengthened since the publication of a Medical Progress article on chemical carcinogenesis in 1971.<sup>1</sup> By the mid-1960s, the view of the cause and pathogenesis of cancer had already begun to change radically from that of previous decades, during which no clear perception of the possible role of the environment in the genesis of most of the major forms of cancer was evident. Although the relation of cancer to environmental hazards in the work place and to a few unusual cultural patterns around the world was established, the examples were considered exceptional.

The general acceptance of cigarette smoking as a major factor in the development of lung cancer and the increasing number of examples of major shifts in the organ or tissue distribution of primary cancers with migration of distinctive ethnic groups from one

geographic location to another were important in changing the whole perception of the genesis of cancer.<sup>2,3</sup>

This radical change has encouraged increasing attention to the nature of the environmental influences. The available epidemiologic evidence indicates the likelihood of several (if not many) components in this environmental outlook. Diet, carcinogenic chemicals, radiation, and viruses are among the major factors that appear to be involved. Of these, chemicals as carcinogens have been receiving increasing attention as having the greatest role in the genesis of cancer. How justified is this perception of the causation of cancer?

About one third of the cancer in North America and Europe is related to the use of cigarettes or other tobacco products. There is incontrovertible evidence that chemicals related to the work place or occupation are responsible for a segment of cancer in human beings (Table 1). To these must be added a growing list of naturally occurring chemicals and of drugs used in medicine. All these known agents, together with ultraviolet light as the single most common cause of cancer, can easily account for over 50 per cent of the cases

From the departments of Pathology and Biochemistry, University of Toronto, 100 College St., Toronto, ON M5G 1L5, Canada, where reprint requests should be addressed.

Supported by research grants from the National Cancer Institute of Canada, the Medical Research Council of Canada, and the National Cancer Institute (U.S.A.).

Table 1. Chemicals Known or Strongly Suspected to be Carcinogenic for Human Beings.

| Chemical           | Sites of Cancer                                                    |
|--------------------|--------------------------------------------------------------------|
| Alkylating agents  | Bladder                                                            |
| Aromatic amines    | Skin and bladder                                                   |
| Benzene            | Bronchus, pleura, and peritoneum                                   |
| Chloroform         | Marrow                                                             |
| Chromosomal agents | Bronchus                                                           |
| Chromosomal agents | Respiratory tract                                                  |
| Coccarbonyl        | Prostate                                                           |
| Coccarbonyl        | Bronchus                                                           |
| Coccarbonyl        | Bronchus                                                           |
| Coccarbonyl        | Bronchus and pleura                                                |
| Coccarbonyl        | Skin and lungs                                                     |
| Coccarbonyl        | Nasal sinuses                                                      |
| Coccarbonyl        | Liver                                                              |
| Coccarbonyl        | Bladder                                                            |
| Coccarbonyl        | Hematopoietic tissue                                               |
| Coccarbonyl        | Liver                                                              |
| Coccarbonyl        | Skin                                                               |
| Coccarbonyl        | Bladder                                                            |
| Coccarbonyl        | Vagina                                                             |
| Coccarbonyl        | Lymphoid tissue                                                    |
| Coccarbonyl        | Reproductive system                                                |
| Coccarbonyl        | Liver                                                              |
| Coccarbonyl        | Bronchus, mouth, pharynx, larynx, esophagus, bladder, and pancreas |
| Coccarbonyl        | Liver                                                              |
| Coccarbonyl        | Mouth                                                              |

in the United States, Canada, and several other western countries.

What about the remaining cancers — those in the breast, uterus, hematopoietic-lymphoid system, prostate, and other sites, including a substantial proportion of those in the urinary bladder and pancreas? Can they be closely related to the chemical contamination of the air, water, and food that has been occurring in the industrialized countries?<sup>4,5</sup> No definitive answer is available. Evidence can be offered in favor of such a view or against it.

On the positive side are the following considerations: the known relation, mentioned above, between many different types of cancer and exposure to chemicals in tobacco and in the work place; the widespread presence of chemical mutagens and potential carcinogens in the environment in industrialized countries, as monitored by short-term *in vitro* tests in prokaryotes or eukaryotes; the observations that some religious groups in Utah and elsewhere, who have different patterns of tobacco and alcohol use and different codes of behavior, appear to have a lower incidence of some forms of cancer in the respiratory, gastrointestinal, and genitourinary systems<sup>6</sup>; the increasing evidence that cancers of many systems, resembling cancers in human beings, can be induced by chemical carcinogens in one or more laboratory animals; and the observations that cancers of the esophagus or liver have an unusually high incidence in some geographic locations in China, and that domestic ani-

mals in close contact with human beings in these locations frequently have similar cancers in the same anatomic sites.<sup>7-10</sup>

On the negative side, no clear-cut clinical experimental or epidemiologic evidence has been presented to implicate environmental chemicals as causative agents for the wide variety of cancers seen clinically. According to German<sup>11</sup> and Cairns,<sup>12</sup> patients with xeroderma pigmentosum, who have a defect in their mechanisms in the repair of DNA damage by some chemicals as well as by ultraviolet light, have no elevated risk of cancer in organs or tissues other than the skin. If the general environmental exposure to chemicals were effective in the causation of cancer, such patients could be expected to have elevated incidences of cancer not related to ultraviolet light. In some cancers, such as leukemia and cancers of the stomach and cervix, there were decreases in age-adjusted incidence and in mortality from 1969 to 1971 and from 1972 to 1976 among white persons in the United States, while there were only small increases in most of the other tumors, as compared with cancers of the lung and with melanoma.<sup>13</sup> No increase comparable to that of lung cancer has been seen in the past two decades in the patterns of cancer incidence in the United States.

None of the above considerations are by any means conclusive. Most of the arguments on either side have enough contingencies to leave the question in major doubt. The close monitoring of cancer occurrence over the next two decades may allow a more definitive position to be taken. In the meantime, a greater understanding of how chemicals are involved in cancer development would seem important in helping us to arrive at a conclusive position.

In addition, the large increase in the use of chemical carcinogens in the development of new experimental models for the study of the possible cause, development (pathogenesis), or treatment of cancers in specific organ or tissue sites in human beings further emphasizes the importance of the study of chemical carcinogenesis. Such studies should generate a much more critical understanding of the relative roles of exogenous and endogenous factors, including diet and hormones, in cancer development and behavior.

The orientation in this presentation will be mechanistic, not descriptive, and will attempt to relate fundamental concepts and understanding derived from experimentation in animals and from other sources to the causation, prevention, and (to some degree) therapy of cancer in human beings. For this reason, little coverage will be given to the many different types of chemical carcinogens themselves or to their distribution.<sup>14</sup>

#### CANCER AS A CHRONIC MULTISTAGE PROCESS

It is now appreciated that the development of cancer in human beings in various sites takes many years and that progressive tissue and cellular changes

ST0005471

can be seen during the long so-called latent period. Often, new cell populations appear that probably represent stages or steps in the cellular evolution from normal cells through initiated, preneoplastic, and premalignant cells to highly malignant neoplastic cells.<sup>15-17</sup> Research in laboratory animals has concentrated heavily on the early events and has suggested the existence of common patterns of early preneoplastic changes in several organ systems and in several species.<sup>17</sup> Research in human beings has concentrated largely on the later events and has confirmed the occurrence of atypical hyperplasias, dysplasia, and carcinoma in situ as probable precancerous steps in several organs late in the process.<sup>17-19</sup> However, the critical properties of each different cell population that relate to the possible roles of these cells in cancer development and to the manner in which the two aspects of carcinogenesis (the experimental and the human) fit together into some biologically meaningful pattern remain as challenges.<sup>17</sup>

The conceptual advances made in the late 1930s and 1940s concerning the first two early steps in chemical carcinogenesis, initiation and promotion, are well known.<sup>15-17,20</sup> However, their mechanistic bases are only now unfolding, and these will be topics for review. The basic validity of these concepts for cancer development in human beings has been established in a few instances and as such is reassuring both for the physician and for the scientist. For example, a relatively brief exposure to diethylstilbestrol during pregnancy may be associated with the development of vaginal neoplasia some 15 to 25 years later in the exposed person's daughters.<sup>21</sup> Parenthetically, it should be mentioned that it is not known whether diethylstilbestrol acts in this situation as a chemical carcinogen or whether the effect is predominantly hormonal. Again, a limited exposure for only a few months to a known chemical hazard, such as vinyl chloride, may lead many years later to the appearance of angiosarcoma of the liver.<sup>22</sup> Nonneoplastic cellular and tissue changes are seen during the apparent latent period.

#### INITIATORS AND INITIATION

##### Initiators

Until fairly recently, one of the most puzzling and confusing aspects of chemical carcinogenesis was the diversity in the chemical structure of carcinogens. This problem has now been largely resolved by the discovery of metabolic conversion of many carcinogens to highly reactive metabolites.<sup>23</sup> The best-known form of reactive moieties, generated from several different types of carcinogens, is the "electrophilic reactant," which is a positively charged molecule that reacts well with sites of electron densities in many different cellular components, including DNA, RNA, protein, glutathione, and probably also polysaccharides.<sup>24</sup> A minority of chemical carcinogens, such as

some nitrosamides (e.g., alkyl nitrosourea), bis(chloromethyl) ether, and nitrogen mustard, are active by themselves and do not seem to require any metabolic conversion to more reactive metabolites.

##### Activation and Metabolism of Precarcinogens

The first major type of metabolic activation discovered was the conversion of an aromatic amine, 2-acetylaminofluorene, by *N*-hydroxylation to an *N*-OH derivative.<sup>25</sup> This type of metabolic product is seen with several aromatic amines, including the human bladder carcinogen 2-naphthylamine ( $\beta$ -naphthylamine).

More recently, much effort has been spent on the clarification of the activation of benzo(a)pyrene and the many other polycyclic aromatic hydrocarbons. Many of them are easily generated by burning (pyrolysis), are widely distributed in our environment, and are thought to be partly responsible for the carcinogenicity of coal-tar products, oils, and tars. These compounds undergo epoxidation to form reactive epoxides, some forms of which are considered to be ultimate carcinogens.<sup>22</sup> In the case of benzo(a)pyrene (and probably other polycyclic aromatic hydrocarbons), the initial site of epoxidation may undergo hydration to form a dihydrodiol in a reaction catalyzed by epoxide hydrolase. This inactive derivative, in turn, can be converted to another epoxide at a second site to form a dihydrodiol epoxide. These are considered to be the most likely ultimate carcinogens for at least some polycyclic aromatic hydrocarbons. This series of reactions for benzo(a)pyrene is illustrated in Figure 1. Another potentially important carcinogen for human beings that is subject to activation through epoxidation is aflatoxin B<sub>1</sub>.<sup>26</sup> This substance undergoes oxidation at its 2,3-position, and this derivative, the 2,3-oxide, appears to be one form of ultimate carcinogen of this mycotoxin. Vinyl chloride is also activated through epoxidation.<sup>28</sup>




Figure 1. Current View of the Activation of Benzo(a)pyrene (BP) to Benzo(a)pyrene 7,8-Dihydrodiol-9,10 Epoxide through the Mixed-Function Oxygenase (MFO) System (Cytochrome P-450 System) and Epoxide Hydrolase.

Other types of metabolic conversions are also considered important in carcinogenesis. Nitrosamines are converted to highly reactive alkylating moieties, probably through oxidation. Aromatic or heterocyclic nitro-compounds, such as nitrofurans and 4-nitroquinoline *N*-oxide, probably undergo initial reduction to hydroxy-amino-derivatives. In the case of 4-nitroquinoline *N*-oxide, this form is considered to be an ultimate carcinogen.

For the majority of known conversions, the system most active in the cell is the "mixed-function oxygenase" system, consisting of several cytochromes P-450, reduced nicotinamide-adenine dinucleotide phosphate cytochrome reductase, and lipid.<sup>24</sup> This inducible system is located predominantly in the microsomal fraction of the cell (endoplasmic reticulum), although recent work increasingly points to a second comparable system in the nucleus.<sup>25</sup> In addition to these oxidative systems, reducing systems also exist for some procarcinogens, such as the aromatic or heterocyclic nitro-compounds. Diaphorase or other reduced nicotinamide-adenine dinucleotide phosphate or reduced nicotinamide-adenine dinucleotide reductases are widely distributed among different cells and are effective in reducing the nitro-group to the hydroxy-amino-derivative.

The liver is by far the most active and most versatile organ in the metabolism of procarcinogens and of xenobiotic agents generally. It and other organs have an ability to detoxify potential carcinogens as well as activate them, and the ultimate fate of a chemical depends largely on the balance between activation and inactivation — a balance that is easily modulated in major ways by drugs and other chemicals, age, nutrition, and hormones, as well as genetics.<sup>26-27</sup> For example, the carcinogenicity of several aromatic amines for the liver can be completely prevented by simultaneous exposure to phenobarbital or 3-methylcholanthrene — agents that induce many liver enzymes.<sup>28,29</sup> This phenomenon of resistance of the induced liver to some carcinogens may be of great practical importance to human beings. Virtually all people in the Western world have levels of several xenobiotic agents, such as chlorophenothane, dieldrin, aldrin, polychlorinated biphenyls, and dioxins, in their adipose and other tissues. These agents as a group are effective enzyme inducers in the liver. In addition, many drugs induce various microsomal or other enzymes in the liver or other tissues. Are these inducers making tissues more or less susceptible to the acute toxic or carcinogenic effects of other environmental agents?

The organ or tissue distribution of the carcinogen-metabolizing enzymes may be involved in the organotropism of carcinogens. Since there is an almost certain requirement for activation, and since the metabolic patterns affecting carcinogens and other xenobiotic agents are so variable from cell to cell or from organ to organ, the absolute activities of the various enzymes and especially their relative balance may have key roles in determining which organ will be a

target for a particular carcinogen. An interesting example of modulation at this level is the liver-kidney axis with dimethylnitrosamine. This potent carcinogen normally induces liver cancer when taken through the gastrointestinal tract. However, if the animal is placed on a low-protein diet, the hepatic activation and metabolism fall off. This pattern allows more of the carcinogen to be available for action on the kidney and changes the dominant cancer pattern from the liver to the kidney.<sup>30</sup>

Clearly, the pathologic consequences of exposure to any potentially toxic xenobiotic are related not only to the pathways available for its metabolism but also to the physiologic state at the time of exposure. Thus, the presence of a known mutagen or carcinogen in the environment is by no means synonymous with a mutagenic or carcinogenic response by the exposed person.

#### Possible Molecular Targets for Ultimate Carcinogens

The molecular targets for the electrophilic reactants are many. To date, the bulk of the effort has been concentrated on DNA, with some interest in RNA and protein. In principle, many other molecular targets exist at the macromolecular and "micromolecular" levels. Because of the ease of relating changes in DNA to a permanent change in the biologic behavior of cells, DNA has received the lion's share of attention. Since the first discovery of the chemical nature of an adduct of a carcinogen with nucleic acids in a target organ *in vivo*,<sup>31</sup> there has been an increasing interest in establishing the chemical nature and site of interaction with several different carcinogens.<sup>32</sup> As shown in Figure 2, virtually every potential site for interaction with DNA bases (as well as with phosphates) reacts with one or more carcinogens. In attempts to narrow down the possibilities for relevance to cancer, sites that are more likely to be involved in hydrogen bonding between bases (purines and pyrimidines) in DNA, and thus to be involved in possible miscoding, are often considered most relevant. This presupposes that the major or only biochemical lesion in DNA that is relevant to cancer initiation is a miscoding lesion. This judgment may not be justified, since the evidence is circumstantial and inconclusive. Conceivably, other types of alterations in DNA besides miscoding, such as recombinations and gaps, may be important to the early events in cancer development.<sup>33-35</sup> In fact, Cairns has suggested that mutagenesis may be of only minor importance in the initial events in chemical carcinogenesis, and that genetic transposition including relatively large regions of the genome may be more relevant to this process.<sup>32</sup> The application of this newer technology to appropriate "clean" cell populations during the development of cancer is to be awaited with interest.

Another important aspect is the site of interaction of the ultimate carcinogen within the long DNA molecules. With several different approaches, such as

EST0005473




Figure 2. Diagrammatic Representation of Sites of Interactions of Activated Forms of Carcinogens with the Four Bases of DNA.

T denotes thymine; A, adenine; C, cytosine; G, guanine; MNU, *N*-methyl-*N*-nitrosourea; ENU, *N*-ethyl-*N*-nitrosourea; ENNG, *N*-ethyl-*N'*-nitro-*N*-nitrosoguanidine; 7 Br MBA, 7-bromomethyl-benz(a)anthracene; BP epoxide, benzo(a)pyrene 7,8-dihydrodiol, 9,10-epoxide; 4NQO, 4-nitroquinoline-*N*-oxide; DMS, dimethylsulfate; DMN, dimethylnitrosamine; MMS, methyl methanesulfonate; MNNG, *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine; 1,2DMH, 1,2-dimethylhydrazine; DEN, diethylnitrosamine; N-OH-1-naphthylamine, *N*-hydroxy-1-naphthylamine; 2 AAF, 2-acetylaminofluorene; MAM, methylazoxymethanol; EMS, ethyl methane sulfonate; BPL,  $\beta$ -propiolactone; and MAB, 4-methylaminoazobenzene.

studies of susceptibility to nucleases, separation of transcriptionally active from inactive DNA, or isolation of linker and nucleosome regions in chromatin, some of the interactions of carcinogens with DNA have been found to be nonrandom. However, no single region of high affinity has been found.<sup>38</sup> The use of DNA cloning for specific genes in biologically well-defined preneoplastic and early neoplastic populations should be profitable.

#### DNA Repair

In view of the essentially irreversible nature of initiation with chemicals and the apparent focal nature of the initiation process, major emphasis at the molecular level is given to DNA as a probable target in initiation. However, the evidence is largely circumstantial.

The bulk of evidence comes from studies in patients with xeroderma pigmentosum, who have a high incidence of skin cancers. The etiologic agent is ultraviolet light, and the vast majority of patients have a defect in their ability to repair the damage inflicted on DNA by this form of radiation. Such patients can be protected from skin cancer by careful avoidance of exposure to ultraviolet light.<sup>40</sup> Fibroblast cultures from these patients have increased sensitivity not only to ultraviolet light but also to some chemical carcinogens and mutagens.<sup>41</sup> Other diseases (e.g., ataxia-telangi-

ectasia and Fanconi's anemia) also involve deficiencies in DNA repair as well as an increased risk of neoplasia.<sup>42</sup>

Experimentally, there is a correlation under some conditions between the formation of specific DNA adducts (such as O<sup>6</sup>-methylguanine in the brain), persistence of this biochemical lesion, and the ultimate appearance of gliomas.<sup>43</sup> Other studies indicate that the genesis and persistence of O<sup>6</sup>-methylguanine may be important but is insufficient to account for cancer production with some nitrosamines or nitrosamides<sup>44</sup> or 1,2-dimethylhydrazine.<sup>45</sup>

The major protection against cancer may reside in the efficiency with which we repair DNA that has been damaged by mutagens and carcinogens. As pointed out by German<sup>11</sup> and by Cairns,<sup>12</sup> since fibroblasts from patients with xeroderma pigmentosum show a defect in the repair of DNA damage by some chemicals as well as by ultraviolet light, such patients should have an elevated risk for cancer in organs or tissues other than the skin if chemical carcinogens are important in the genesis of many forms of cancer. Yet the available data show no apparent increase in the risk of cancers other than those of the skin in patients with xeroderma pigmentosum.<sup>12</sup> Patients with Bloom's syndrome do have an elevated risk. Such observations are interpreted as evidence against a role for the many environmental chemical hazards in the causation of human cancers generally, except in well-established instances such as respiratory-tract cancer<sup>12</sup> in smokers and in persons with occupational exposures.<sup>12</sup> An alternative hypothesis must be entertained: that the role of repair may be quite different in the dynamics of cancer induction by chemicals, compared with induction by ultraviolet light.

The past 10 years have seen a large expansion in studies of DNA repair, largely in vitro. These studies should lead to a much clearer delineation of the types of repair that may occur in carcinogenesis. What does happen remains poorly understood. Processes of repair by base excision, by "long-patch versus short-patch" removal, by possible recombination or other forms of post-replication repair, by removal of inter-strand cross-links or other more complex forms of damage, and by other mechanisms are slowly being studied in many different systems in vitro and to a much lesser degree in vivo.<sup>34,41</sup> The enzymology, although difficult, is also slowly becoming clear. In the case of methylating carcinogens, an interesting recent finding is the discovery of an enzyme in bacteria that removes the methyl group from the O<sup>6</sup> position of guanine in DNA by transmethylation with its transfer to a sulfur-containing moiety in protein.<sup>46</sup> This raises the question of whether some of the enzymes involved in repair of DNA damage perform physiologic functions other than repair that subserve normal cellular requirements.

Obvious failings in many of the attempts to correlate patterns of DNA repair with carcinogenicity include the wide gap between the chemistry and the bi-

new and the primitive state of the art of identifying and quantitating discrete biologic steps in the carcinogenic process.

#### Carcinogen Metabolism in Human Tissues

One unifying aspect of recent studies of the early chemical and biochemical events in carcinogenesis is the overall similarity in patterns of activation and types of adducts seen in tissues from human beings and those from laboratory animals. Studies with some nitrosamines, benzo(a)pyrene, aflatoxin B<sub>1</sub>, and other carcinogens<sup>41-43</sup> have shown that human tissues in general resemble one or more animal tissues in their patterns of activation and in the type of carcinogen-DNA adducts formed.

An interesting development that may help to clarify some aspects of this important phase of activation is the use of radioimmunoassays for specific adducts in DNA, especially with highly sensitive new approaches to radioimmunoassay.<sup>44-46</sup> Such detection of minute quantities of carcinogen-induced adducts in DNA opens up the possibility of studying exposure patterns to carcinogens. This technique, coupled with adequate medical examination and appropriate epidemiologic studies, might well offer new approaches to the ultimate problem of risk assessment. Although it is too early to discuss such possibilities except in general terms, adduct formation is an index of exposure, not initiation, and persistence of a chemical lesion in DNA is by no means synonymous with cancer development. As discussed below, initiation of the carcinogenic process is not an inevitable consequence of adduct formation.

Human cells resisted *in vitro* transformation with chemicals for several years. However, the past three years have seen positive results in some human-cell systems.<sup>47-49</sup>

#### Initiation

In the classical system of skin carcinogenesis in mice and rabbits, a single or brief exposure to a carcinogen induces some change in the tissues, called initiation, such that focal proliferations called papillomas can be made to appear by application of croton oil or other agents called promoting agents, which by themselves are noncarcinogenic or only weakly carcinogenic. More recently, this phenomenon was also found in several other organs, such as the liver, brain, mammary gland, colon, and urinary bladder.<sup>16,17</sup> Such focal proliferations (papillomas, polyps, or hyperplastic nodules), in turn, are sites for further evolution to neoplasia. The term neoplastic refers to a cell that can proliferate without the need for an added or known stimulus for growth — i.e., a cell that has acquired some degree of autonomy. Initiation at the skin, liver, and mammary gland, and probably at most sites, is generally permanent. This suggests that the very early carcinogen-induced altered cells are not recognized by the host in a manner that leads to their destruction, and it raises serious doubts about the va-

lidity of the concept of immune surveillance at an early stage in carcinogenesis,<sup>50</sup> as has been proposed for host control of cancer development.<sup>51</sup>

These observations are most easily interpreted as reflecting some permanent change in the DNA in the rare cell affected during initiation *in vivo*. Whether the change is a mutation in a structural or regulatory segment of DNA<sup>52-54</sup> or whether it involves more complex rearrangements of larger segments of DNA, as in transpositions, remains unknown. Pertinent are the observations on transformation initiated with x-rays or with polycyclic aromatic hydrocarbons, in which some change or changes other than a mutation in a rare cell appear to be involved as an early step in initiation *in vitro* with a highly selected cell type.<sup>55,56</sup>

One cannot equate activation of carcinogens leading to DNA-adduct formation with initiation. For example, many carcinogens, such as benzo(a)pyrene and 7,12-dimethylbenz(a)anthracene, can be activated by the liver to form adducts without initiating or inducing liver cancer in adult animals. However, if coupled with one round of cell proliferation, many can initiate<sup>57-59</sup> and induce liver cancer.<sup>60</sup> *In vitro*, with different cell systems, cell proliferation early in the carcinogenic process is required for transformation with x-rays,<sup>61</sup> some viruses,<sup>62</sup> and some chemicals.<sup>63</sup> Thus, as shown in Figure 3, initiation is at least a two-step process: a biochemical step that is reparable, followed by a round of cell proliferation that "fixes" some change so as to make it essentially permanent. The cell proliferation can be generated by some primary mitogenic stimulus, such as partial hepatectomy, by a chemical mitogen,<sup>64</sup> or as a response to cell death.<sup>65</sup> The mechanistic role of cell proliferation in initiation is not understood. A popular hypothesis involves DNA synthesis or replication as somehow fixing damage in a daughter strand.

The probable requirement for cell proliferation for initiation has important implications for cancer development in many sites. In the nonproliferating tissues, such as the pancreas, salivary gland, liver, kidney, urinary bladder, and brain, an important rate-limiting step for beginning the carcinogenic process may be cell proliferation. Thus, concomitant cell ne-




Figure 3. Steps in the Initiation of Carcinogenesis with Chemicals.

The listings under "Initiation" refer to some properties either used in the next phase, promotion (liver), or associated with the initiated tissue (skin or colon).

EST0005475

crosses induced by viruses, toxic agents, parasites, or dietary deficiencies, followed by cell regeneration, could be a major determinant of cancer initiation in many sites. In addition, the presence of many proliferating cells is probably one basis for the susceptibility of the fetus and neonate to many chemical carcinogens<sup>18</sup> and could account for the peak in cancer incidence in the first decade of life. The human fetus, unlike the rodent fetus, acquires the capability of activation of some carcinogens early in development<sup>19,20</sup> and thus may be at greater risk than some laboratory animals for cancer development with chemicals.

A most important question about initiation concerns the essential biologic nature of the initiated cells. What properties have they acquired that allows them, as a group, to be precursors for the ultimate development of cancer? The available evidence is against any conclusion that the initiated cells have acquired any autonomy of growth.<sup>15,17</sup>

In most systems, the properties critical to initiation remain unknown. In two continuously proliferating tissues, the skin<sup>21</sup> and the colon,<sup>22</sup> an early property of carcinogen-altered cells may be some disturbance in programming or control, such that the cells do not show the normal progression of differentiated properties. In the liver, the cell with acquired resistance to the inhibitory effects of carcinogens on cell proliferation has been shown to be one type of initiated cell.<sup>17,23</sup>

Although a majority of chemical carcinogens fall well within the current paradigm in which initiating effects are related to some form of DNA damage, there are known carcinogens that appear to be exceptions. A growing list of hypolipidemic agents<sup>24</sup> and several pesticides, herbicides, and other xenobiotics<sup>25</sup> have not been shown to generate mutagenicity or other DNA-damaging effects. Is this merely a reflection of deficiencies in our technology, or are there pathways to cancer that do not involve DNA damage of exogenous origin as essential early steps in the process?

#### PROMOTERS AND PROMOTION

The term "promotion" is often used for the process whereby neoplastic development, tumor formation, or cancer development is accelerated or encouraged in a tissue that has been exposed to an initiating dose or doses of a carcinogen.

##### Promoters

Early in the recent history of chemical carcinogenesis it was found that a noncarcinogen, croton oil, could stimulate tumor formation in the skin after a brief initial exposure to a carcinogen. This naturally encouraged a chemical "attack" on croton oil. Hecker<sup>26</sup> and Van Duuren<sup>27</sup> discovered that esters of the diterpene phorbol, isolated from croton oil, have potent promoting effects on mouse skin. Many biochemical, metabolic, and biologic effects are induced in many different normal cells by the phorbol esters and related compounds; in the vast majority of cases, the intensity of the particular effect closely parallels

the efficacy of the compounds as promoters of skin papillomas in mice after exposure to a single dose of dimethylbenzanthracene or a similar carcinogen.<sup>28,29</sup> These effects include changes in morphology, microtubule polymerization, cell proliferation, enzyme induction, polyamine synthesis, phospholipid synthesis, membrane structure and function, ATPase, release of prostaglandins, inhibition and sometimes stimulation of differentiation, and many others in a wide variety of normal cells and cell lines. Many of the effects are considered pleiotropic.

Recently, with the use of a less active phorbol ester, <sup>3</sup>H-phorbol dibutyrate, membranes of fibroblast cultures and mouse epidermal cells were found to contain a high-affinity receptor for many phorbol esters, including one of the most active, 12-O-tetradecanoylphorbol-13-acetate.<sup>30,31</sup> The "natural" metabolites for the receptors have not been identified. Given the wide diversity and large number of effects seen in treated cells, it may be that more than one type of receptor is involved.

At present it is impossible to relate the findings *in vitro* to chemical carcinogenesis *in vivo*. Given the array of phenomena induced by the phorbol esters, how does one select relevance to promotion?

A major problem concerns the matching of the target cells *in vivo* and *in vitro*. In the intact animal, an active promoter does not induce focal proliferations (such as papillomas) in the normal skin, but does so only after initiation. However, many skin promoters do induce general hyperplasia of the epidermis in animals in which initiation has not taken place. Studies in several laboratories have shown that a general stimulation of cell proliferation is insufficient for the selective or differential stimulation of initiated skin to form papillomas.<sup>32</sup>

##### Promotion

A question that requires an early answer is whether the differential effect of a promoting environment on initiated tissues is directed primarily to the initiated cells or to the surrounding cells.<sup>33</sup> There is considerable circumstantial evidence to suggest that the first major phenomenon in promotion is the selection of an appropriately altered cell to produce a focal proliferation, and that promoting environments create differential effects on the initiated cells and on the surrounding cells.<sup>17,23,34</sup> Cancer frequently arises in an atrophic tissue or organ, not a hypertrophic one. Is this the consequence of a change in the local environment, favoring growth of the rare initiated cell?

As observed *in vivo* in experimental models in common use today, cell proliferation is an essential phenomenon in promotion. It is therefore to be anticipated that many biochemical changes that are seen in the different phases of the cell cycle,<sup>35</sup> such as an increase in ornithine decarboxylase activity, will be seen in promotion. Determining whether one or more of such changes in enzymes, the cell membrane, DNA organization, or other factors will have a special role in pro-

ST0005476

over and above that related to the cell cycle remains an interesting challenge.

There is a growing belief that one of the major factors in determining cancer development is the presence and intensity of promoting environments.<sup>94</sup> In addition to some specific agents such as phenobarbital,<sup>95</sup> 3-methylcholanthrene, and polychlorinated biphenyls for the liver,<sup>96</sup> prolactin for the mammary gland,<sup>97</sup> and bile acids for the colon,<sup>98,99</sup> diet has been found to influence carcinogenesis in several systems.<sup>100</sup> However, the specific roles of individual dietary components and of their balances remain to be established in most instances.

There is also a suspicion on the part of some investigators that tissues or organs may create a physiologic promoting or selecting environment. The most provocative evidence relates to carcinogenesis in the colon<sup>101,102</sup> and the urinary tract.<sup>103,104</sup> In each of these locations, diversion of the normal movement of contents has been found to lead to a decreased incidence of neoplasia with known carcinogens.

There are several examples in which synergism or promotion may be operating in human beings. For example, exposure to asbestos, nickel, or uranium may be associated with only a relatively low risk of lung cancer. However, when coupled with cigarette smoking, the risk becomes extremely large — much larger than that associated with smoking alone.

#### Progression Steps

##### Progression

Focal proliferative lesions resulting from a promoting environment, such as papillomas, nodules, or polyps, undergo a number of further changes before malignant behavior is expressed.

In many organs, including the bronchial tree in the smoker, one consistently sees several types of putative precancerous lesions, such as atypical hyperplasias, dysplasias, and carcinoma in situ.<sup>105</sup> How these lesions relate to each other and to altered biologic behavior of cells transformed in vitro (e.g., atypical growth, growth in soft agar, or tumorigenicity) is not clear and remains a potentially fruitful area for study.

An important property of many of these changes is reversibility. There is considerable evidence in experimental models and in human beings that some focal proliferative lesions, such as hyperplastic nodules in the liver (and their probable human equivalent, liver "adenomas," which are seen rarely in women using oral contraceptives), polyps in the colon, and papillomas in the skin, can undergo regression or remodeling with normal differentiation.<sup>106,107</sup> This area is becoming of particular interest in view of the reported efficacy of vitamin A analogues, such as *all-trans*-retinoic acid, in preventing or delaying cancer development initiated with chemical carcinogens<sup>108</sup> in several sites, such as the bronchus and the urinary bladder.

##### Transfection

An interesting recent development is the induction of transformation by the transfer of DNA or chroma-

tin to susceptible cell lines. DNA from several types of cells transformed in vitro or in vivo with different carcinogens was shown to induce transformation.<sup>109,110</sup> Of great interest is the observation that DNA from normal cells was also effective.<sup>110</sup> These new approaches in chemical carcinogenesis open up many areas of exploration, including the question of whether the information contributions of the DNA are positive (i.e., they code for an identifiable component that is important in cell transformation) or negative (i.e., they disorganize the host genome in an appropriate manner).

#### Diet and Carcinogenesis

The composition of the diet may influence the incidence of cancer in some sites, such as the colon, breast, and endometrium.<sup>107-109</sup> The mechanism or mechanisms through which diets exert their influences are not well understood. In some instances, carcinogens occur in the food as natural substances, as contaminants (e.g., aflatoxins), or as products of food-preparation methods (e.g., pyrolysis). Dietary alterations also modulate the activation of carcinogens.

In other instances, micronutrients have a role in the endogenous formation of carcinogens. The past 10 years or so have seen a revival of the concept of the endogenous formation of carcinogens. This hypothesis was proposed in the 1930s in relation to cholesterol or other sterols, but it was progressively abandoned as the evidence failed to materialize. The resurrection of this idea assumes a new form in the genesis of nitroso-compounds from nitrite and secondary or tertiary amines.<sup>110</sup> Dietary amines or drugs such as oxytetracycline or chlorpromazine can react with nitrous acid, generated in the stomach from nitrite, to form nitroso-compounds. Some of these substances are carcinogenic in laboratory animals. The formation of such nitroso-compounds can be effectively inhibited by dietary ascorbic acid<sup>111</sup> and by vitamin E.

This general model is being explored in colon cancer in human beings.<sup>112</sup> The hypothesis states that carcinogens can be generated in the feces and that the levels of the carcinogens, as measured by mutagenic action, are influenced by the dietary composition, including vitamins C and E and fiber content.

#### Chemotherapy and Carcinogenesis

Some of the most effective chemotherapeutic agents for cancer are carcinogenic. For the treatment of cancer in patients above 50 or 60 years old, the importance of the risk of carcinogenicity is clearly minimal, given the long latent period for cancer development. However, in children and young adults, the development of second cancers years after the effective treatment of the primary tumor is now becoming a recognizable problem.<sup>113,114</sup> Over 25 drugs used in chemotherapy have been found to be carcinogenic in animals, and some have also been implicated in human beings.

The magnitude of the risk associated with the many treatment regimens is not fully known. However, for

EST0005477

some patients the risk of second primary tumors varies from 7 to 12 per cent.<sup>113</sup> These figures include some risk factors aside from the therapy, that are possibly genetic and favor second or multiple primary tumors. However, there is an additional risk from the chemotherapy itself. This risk will increase in volume as current types of chemotherapy for cancer become more successful. However, as mechanisms by which chemicals induce cancer and kill cancer cells are clarified, ways will be found to prevent the carcinogenic effects without interfering with the drugs' efficacy in treating cancer.

A common problem in cancer chemotherapy is the appearance of resistant cancer cells. Since resistant cells are also produced by carcinogens during carcinogenesis, and since such resistance constitutes one form of initiation,<sup>17,23</sup> it is conceivable that the induction of resistance to therapy and that of cancer are related.

#### NEW BIOASSAYS FOR CARCINOGENS AND PROMOTERS

The basic knowledge that has been generated during the past 20 years or so has spawned a large array of short-term tests (mostly in vitro) for potential carcinogens, and more recently for promoters.<sup>114</sup> These tests generally fall into two broad groups: those that use some correlate of DNA damage or chromosomal damage as end points and those that use cell transformation as the end point.<sup>114-118</sup> The majority require the inclusion of an appropriate activation system.

This development is an essential requirement for rapid monitoring of our environment. In addition, these tests are being used increasingly as rapid assays for some more basic aspects of chemical carcinogenesis, such as patterns of activation in tissues and the endogenous production of carcinogens or mutagens, to name but two of many examples.

#### CONCLUSIONS

The past decade has produced new insights into the need for metabolic activation, the nature of the active molecules, the enzymology of activation, and the array of products generated, including major ultimate carcinogens. The interactions of such derivatives with DNA and other cell constituents and the possible toxicities and other effects on cells are becoming clearer. There is a general belief that DNA damage is involved in cancer initiation in most instances. The basic studies have generated over 100 short-term assays for possible carcinogens, with many of the assays reflecting damage to DNA or chromosomes.

The importance of the modulation of metabolic activation by enzyme induction with hormones, diet, drugs, and chemicals (including many environmental contaminants such as pesticides, herbicides, and polychlorinated biphenyls) is appreciated. How this ubiquitous exposure may influence cancer development in human beings is not known.

The repair of lesions in DNA is receiving increasing emphasis. The majority of such studies are in rel-

atively simple in vitro systems and are generating insights into what may happen. The study of what does happen remains a major challenge. It may be aided by the development of ultrasensitive enzymatic radioimmunoassays for carcinogen-DNA adducts.

There is an increasing realization that many post-initiation phenomena, including promotion, are of major importance in cancer development. Alterations in diet, hormones, drugs, and xenobiotic agents have major influences through effects on promotion and other later steps. The reversibility of many of the pre-cancerous steps is being studied with vitamin A and its analogues and with other dietary components.

Despite the major advances, the study of the later phases of chemical carcinogenesis lags far behind that of the early biochemical events. A nagging uncertainty in this field in general concerns the role of chemical carcinogens of either exogenous or endogenous origin in the causation and pathogenesis of some of the major forms of cancer. There is a general agreement that cigarette smoking and ultraviolet light are two major factors in the genesis of several important types of cancers. There is also incontrovertible evidence that many chemicals to which persons are exposed in the work place or its environs cause cancer in several organ systems. However, the relative quantitative importance of these considerations in the majority of patients with cancer not related to smoking is unclear. The resolution of this problem, although no doubt difficult, will almost certainly have a major impact on our approaches to cancer prevention in coming decades.

I am indebted to Miss Hélène Robitaille for assistance in the preparation of this manuscript and to my colleagues, Drs. A. Medicine and D. S. R. Sarma, for their critical comments.

#### REFERENCES

1. Ryser HJ-P. Chemical carcinogenesis. *N Engl J Med.* 1971; 285:721-34.
2. Fraumeni JF Jr, ed. *Persons at high risk of cancer: an approach to cancer etiology and control.* New York: Academic Press, 1975.
3. Doll R. The epidemiology of cancer. *Cancer.* 1980; 45:2475-85.
4. Peto R. Distorting the epidemiology of cancer: the need for a more balanced overview. *Nature.* 1980; 284:297-300.
5. Epstein SS, Swartz JB. Fallacies of lifestyle cancer theories. *Nature.* 1981; 289:127-30.
6. Populations at low risk of cancer. *J Natl Cancer Inst.* 1980; 65:1055-195.
7. Kaplan HS, Tsuchitani PJ, eds. *Cancer in China.* New York: Alan R. Liss, 1978.
8. Yang CS. Research on esophageal cancer in China: a review. *Cancer Res.* 1980; 40:2633-44.
9. Cheng S-J, Sala M, Li MH, Wang M-Y, Pot-Dupren J, Chouroulinkov I. Mutagenic, transforming and promoting effect of pickled vegetables from Liaixian county, China. *Carcinogenesis.* 1980; 1:685-92.
10. Cheng SJ, Sala M, Li MH, Courtion I, Chouroulinkov I. Promoting effect of Roussin's red identified in pickled vegetables from Liaixian China. *Carcinogenesis.* 1981; 2:313-9.
11. German J. Cancer in chromosome-breakage syndromes. Presented at the 6th International Congress on Radiation Research, Osaka 5, ed. Tokyo, Japanese Association for Radiation Research, 1979.
12. Cairns J. The origin of human cancers. *Nature.* 1981; 289:353-7.
13. Pollack ES, Horn JW. Trends in cancer incidence and mortality in the United States, 1969-76. *J Natl Cancer Inst.* 1980; 64:1091-103.
14. IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans. Lyon: International Agency for Research on Cancer, 1972-1980.
15. Fouls L. Neoplastic development. Vol. 1, 2. New York: Academic Press, 1969, 1975.

40. HC. Biological and enzymatic events in chemical carcinogenesis. *Annu Rev Med*. 1979; 30:25-37.
41. Farber E, Cameron R. The sequential analysis of cancer development. *Adv Cancer Res*. 1980; 31:225-226.
42. Voss LG. Preneoplastic lesions. *Cell*. 1980; 21:1-10.
43. Medline A, Farber E. Multi-step theory of neoplasia. *Recent Adv Histopathol*. 1974; 11:19-34.
44. Miller AC. Some current perspectives on chemical carcinogenesis in humans and experimental animals. Presidential address. *Cancer Res*. 1978; 38:1479-95.
45. Ames BN, Pratt J, Robbey SJ, Herbst AL. Pathology of premalignant dysplastic lesions. *Pathol Annu*. 1978; 13:201-14.
46. Casanova M, Hakkio EC, eds. Toxicity of vinyl chloride-polyvinyl chloride. *Ann NY Acad Sci*. 1979; 344:1-337.
47. Gelboin HV, To P. POP. eds. Polycyclic hydrocarbons and cancer. Vol. 1 and 2. New York: Academic Press, 1978.
48. Li AYH, West SB. Multiplicity of mammalian microsomal cytochromes P-450. *Pharmacol Rev*. 1979; 31:271-93.
49. Brannick E. Nuclear metabolism of polycyclic hydrocarbons and interaction of polycyclic hydrocarbons with nuclear components. *Adv Carcinog Res*. 1978; 16:347-61.
50. Weinstein IB. Inhibitors of chemical carcinogenesis. *Adv Cancer Res*. 1973; 23:97-228.
51. Weinberger JM, Williams GM. Metabolism of chemical carcinogens. In: Becker FF, ed. *Cancer: a comprehensive treatise*. Vol. 1. New York: Plenum Press, 1975:165-204.
52. Li AYH, West SB, Ryan D, et al. Properties of the liver microsomal monooxygenase system and effects of hydrocarbons influencing the metabolism and mutagenicity of benzo(a)pyrene. In: Hsu HH, Watson JD, Winkler JA, eds. *Origins of human cancer*. Vol. 4. New York: Cold Spring Harbor Laboratory, 1977:659-82.
53. Bentley P, Osach F. Enzymes involved in activation and inactivation of carcinogens and mutagens. In: Remmer H, Yoh HM, Bannasch P, Farber E, eds. *Primary liver tumors*. Baltimore: University Park Press, 1978:239-52.
54. Schuster-Hermann R. Reactions of the liver to injury: adaptation. In: Farber E, Farber NM, eds. *Toxic injury of the liver*. New York: Marcel Dekker, 1979:383-444.
55. Farber E. Toxicological significance of liver hypertrophy produced by inducers of drug-metabolizing enzymes. *Ciba Found Symp*. 1980; 76:261-74.
56. Environmental chemicals, enzyme function and human disease. *Ciba Found Symp*. 1980; 76:1-380.
57. Weinstein IB, Loub WD, Lam LK, Spier JL. Dietary constituents altering the responses to chemical carcinogens. *Fed Proc*. 1976; 35:1327-31.
58. Mages AEM, Magee PN. Increased renal carcinogenesis by dimethylnitrosamine in protein deficient rats. *Br J Exp Pathol*. 1970; 51:587-90.
59. Magee PN, Farber E. Toxic liver injury and carcinogenesis: methylation of rat-liver nucleic acids by dimethylnitrosamine *in vivo*. *Biochem J*. 1968; 103:114-24.
60. Rajeshkumar S, Rao PM, Sarma DSR. Chemical carcinogenesis: interactions of carcinogens with nucleic acids. In: Becker FF, ed. *Cancer: a comprehensive treatise*. 2d ed. Vol. 1. New York: Plenum Press, 1975:165-204.
61. Farber E. N-nitroso alkylating agents: formation and persistence of alkyl derivatives in mammalian nucleic acid as contributing factors in carcinogenesis. *J Natl Cancer Inst*. 1979; 62:1329-39.
62. Jewell PD. Approaches to chemical dosimetry in mutagenesis and carcinogenesis: the relevance of reactions of chemical mutagens and carcinogens with DNA. In: Grover PL, ed. *Chemical carcinogens and DNA*. Vol. 1. Boca Raton, Fla: CRC Press, 1978:1-34.
63. Marnett LJ. DNA — the critical cellular target in chemical carcinogenesis? In: Grover PL, ed. *Chemical carcinogens and DNA*. Vol. 2. Boca Raton, Fla: CRC Press, 1979:159-79.
64. Takabe H. Genetic complementation tests for Japanese xeroderma pigmentosum patients and their skin cancers and DNA repair characteristics. In: Magee PN, Takayama S, Sugimura T, Matsushima T, eds. *Fundamentals in cancer prevention: 7th International Symposium of the Princess Takamatsu Cancer Research Fund*. Tokyo: University of Tokyo Press, 1973:383-93.
65. Maher VM, McCormick JJ. DNA repair and carcinogenesis. In: Grover PL, ed. *Chemical carcinogens and DNA*. Vol. 2. Boca Raton, Fla: CRC Press, 1979:133-58.
66. Gorman J, ed. *Chromosomes and cancer*. New York: John Wiley, 1974.
67. Gith R, Rajesky MF. Persistence of O<sub>6</sub>-ethylguanine in rat-brain DNA: correlation with nervous system-specific carcinogenesis by ethylnitrosourea. *Proc Natl Acad Sci USA*. 1964; 51:439-43.
68. Buchseler J, Kleihues P. Excision of O<sub>6</sub>-methylguanine from DNA of various mouse tissues following a single injection of N-methyl-N-nitrosourea. *Chem Biol Interact*. 1977; 16:325-33.
69. Ying TS. Studies on acute cell injury, cell replication and DNA repair during initiation of liver carcinogenesis (Ph.D Thesis). Toronto: University of Toronto, 1980.
70. Olsson M, Lindahl T. Repair of alkylated DNA in *Escherichia coli*: methyl group transfer from O<sup>6</sup>-methylguanine to a protein cysteine residue. *J Biol Chem*. 1980; 255:10569-71.
71. Csanady AH, Levin W. Carcinogen metabolism in experimental animals and man. In: Montesano R, Tomatis L, Davis W, eds. *Chemical carcinogenesis essays*. Lyon: International Agency for Research on Cancer, 1974:3-22. (IARC scientific publications no. 10).
72. Montesano R, Migge PN. Comparative metabolism *in vitro* of nitroaromatics in various animal species including man. In: Montesano R, Tomatis L, Davis W, eds. *Chemical carcinogenesis essays*. Lyon: International Agency for Research on Cancer, 1974:39-56. (IARC scientific publications no. 10).
73. Shiohara K, Csanady AH. Formation of benzo(a)pyrene-DNA adducts in peripheral human lung tissue. *Cancer Lett*. 1977; 3:303-9.
74. Pugh RA, Paulus W, Okita RT, Masters BS, Jakobsson SW. Characteristics of benzo(a)pyrene metabolism by kidney, liver, and lung microsomal fractions from rodents and humans. *Cancer Res*. 1979; 39:1199-206.
75. Aulup H, Schwartz MD, Essigman JM, Smith L, Trump BF, Harris CC. Metabolism of aflatoxin B<sub>1</sub>, benzo(a)pyrene and 1,2-dimethylhydrazine by cultured rat and human colon. *Teratogenesis Carcinogenesis Mutagenesis*. 1980; 1:1-13.
76. Aulup H, Jeffrey AM, Harris CC. Metabolism of benzo(a)pyrene in cultured human bronchus, trachea, colon and esophagus. In: Bjørseth A, Dennis AJ, eds. *Polynuclear aromatic hydrocarbons*. New York: Raven Press, 1980; 4:9-105.
77. Moss MJ, Rodgers NT, Kaufman DG. Benzo(a)pyrene metabolism in organ cultures of human endometrium. *Chem Biol Int*. 1981; 33:195-205.
78. Hsu IC, Poirier MC, Yuspa SH, Yelken RH, Harris CC. Ultra-sensitive enzymatic radioimmunoassay (USERIA) detects femtomoles of acetylaminofluorene-DNA adducts. *Carcinogenesis*. 1981; 1:425-8.
79. Poirier MC, Dubin MA, Yuspa SH. Formation and removal of specific acetylaminofluorene-DNA adducts in mouse and human cells measured by radioimmunoassay. *Cancer Res*. 1979; 39:1377-81.
80. Hsu IC, Poirier MC, Yuspa SH, et al. Measurement of benzo(a)pyrene DNA adducts by enzyme immunoassays and radioimmunoassay. *Cancer Res*. 1981; 41:1091-5.
81. Kakunaga T. Neoplastic transformation of human diploid fibroblast cells by chemical carcinogens. *Proc Natl Acad Sci USA*. 1978; 75:1134-8.
82. Mile GE Jr, DiPaolo JA. Neoplastic transformation of human diploid cells *in vitro* after chemical carcinogen treatment. *Nature*. 1978; 275:130-2.
83. Kopelovich L, Bias NE, Nelson L. Tumour promoter alone induces neoplastic transformation of fibroblasts from humans genetically predisposed to cancer. *Nature*. 1979; 282:619-21.
84. Mile GE, DiPaolo JA. Presensitization of human cells with extrinsic signals to induce chemical carcinogenesis. *Int J Cancer*. 1980; 26:805-12.
85. McCormick JJ, Silinskis KC, Kately SA, Tower JE, Maher VM. The induction of anchorage independent growth and tumor formation of diploid human fibroblasts by carcinogens. *Proc Am Assoc Cancer Res Am Soc Clin Oncol*. 1981; 22:122. abstract.
86. Stutman O. Immunosuppression and malignancy. *Adv Cancer Res*. 1975; 22:261-422.
87. Thomas L. Discussion. In: Lawrence HS, ed. *Cellular and humoral aspects of the hypersensitive states*. New York: Harper & Row, 1959:529-32.
88. Cairns J. Mutation selection and the natural history of cancer. *Nature*. 1975; 255:197-200.
89. Nowell PC. The clonal evolution of tumor cell populations: acquired genetic liability permits stepwise selection of variant sublines and underlies tumor progression. *Science*. 1976; 194:23-8.
90. Burnet FM. Cancer: somatic-genetic considerations. *Adv Cancer Res*. 1978; 28:1-29.
91. Kennedy AR, Fox M, Murphy G, Little JB. Relationship between x-ray exposure and malignant transformation in C3H 10T½ cells. *Proc Natl Acad Sci USA*. 1980; 77:7262-6.
92. Mendel S, Heidelberger C. *In vitro* malignant transformation by methylnitrosourea of the progeny of single cells derived from C3H mouse prostate. *Proc Natl Acad Sci USA*. 1970; 65:219-23.
93. Cayama E, Tsuda H, Sarma DSR, Farber E. Initiation of chemical carcinogenesis requires cell proliferation. *Nature*. 1978; 275:60-2.
94. Tsuda H, Lee G, Farber E. Induction of resistant hepatocytes as a new principle for a possible short-term *in vivo* test for carcinogens. *Cancer Res*. 1980; 40:1157-64.
95. Emmelot P, Scherer E. The first relevant cell stage in rat liver carcinogenesis: a quantitative approach. *Biochim Biophys Acta*. 1980; 605:247-304.
96. Craddock VM. Cell proliferation and experimental liver cancer. In: [illegible]

EST0005479

- Cameron HM, Linsell DA, Warwick GP, eds. Liver cell cancer. Amsterdam: Elsevier Scientific Publishing, 1974:153-201.
73. Berez C, Sachs L. *In vitro* cell transformation by X-irradiation. *Nature*. 1964; 210:276-8.
  74. Toozs J. The molecular biology of tumor viruses. New York: Cold Spring Harbor Laboratory, 1973.
  75. Kakunaga T. Requirement for cell replication in the fixation and expression of the transformed state in mouse cells treated with 4-azoxanoline-1-oxide. *Int J Cancer*. 1974; 14:736-42.
  76. Ying TS, Sarma DSR, Farber E. Role of acute hepatic necrosis in the induction of early steps in liver carcinogenesis by diethylnitrosamine. *Cancer Res*. 1981; 41:2096-101.
  77. Columbano A, Rajalakshmi S, Sarma DSR. Requirement of cell proliferation for the initiation of liver carcinogenesis as assayed by three different procedures. *Cancer Res*. 1981; 41:2079-83.
  78. Riser JM, ed. Perinatal carcinogenesis. *Natl Cancer Inst Monogr*. 1979; 31:3-232.
  79. Neubert D, Merker H-J, Nau H, Langman J, eds. Role of pharmacokinetics in prenatal and perinatal toxicology. Stuttgart: Georg Thieme, 1978.
  80. Pelkonen O. Environmental influences on human foetal and placental xenobiotic metabolism. *Eur J Clin Pharmacol*. 1980; 18:17-24.
  81. Berenblum I. A speculative review: probable nature of promoting action and its significance in the understanding of the mechanisms of carcinogenesis. *Cancer Res*. 1954; 14:471-7.
  82. Lipkin M, Dechmer E. Early proliferative changes in intestinal cells. *Cancer Res*. 1976; 36:2645-8.
  83. Farber E. The sequential analysis of liver cancer induction. *Biochim Biophys Acta*. 1980; 605:149-64.
  84. Reddy JK, Azarnoff DL, Higazi CE. Hypolipidemic hepatic peroxisome proliferators form a novel class of chemical carcinogens. *Nature*. 1980; 283:397-8.
  85. Ruzius SJ, Legator MS. Chemical characterization of 465 known or suspected carcinogens and their correlation with mutagenic activity in the *Salmonella typhimurium* system. *Cancer Res*. 1979; 39:3229-318.
  86. Hexter E. Biochemical mechanism of tumor promotion. In: Slaga TJ, Sivak A, Boutwell RK, eds. Mechanisms of tumor promotion and co-carcinogenesis. Vol. 2. New York: Raven Press, 1978:433-42.
  87. Van Duuren BL. Tumor-promoting and co-carcinogenic agents in chemical carcinogenesis. In: Searle CE, ed. Chemical carcinogenesis. Washington: D.C.: American Chemical Society, 1976; 173:24-31.
  88. Blumberg PM. *In vitro* studies on the mode of action of phorbol esters, potent tumor promoters. *CRC Crit Rev Toxicol*. 1980; 8:153-97.
  89. Weinstein IB, Mufson RA, Lee L-S, Fisher PB, Laskin J, Horowitz AD, Ivanovic V. Membrane and other biochemical effects of the phorbol esters and their relevance to tumor promotion. In: Pullman B, Te'o POP, Gelboin H, eds. Carcinogenesis: fundamental mechanisms and environmental effects. Amsterdam: Reidel, 1981:543-63.
  90. Shoyab M, Todaro GJ. Specific high affinity cell membrane receptors for biologically active phorbol and inganol esters. *Nature*. 1980; 284:451-3.
  91. Boutwell RK. The function and mechanism of promoters of carcinogenesis. *CRC Crit Rev Toxicol*. 1974; 2:419-43.
  92. Farber E. Sequential events in chemical carcinogenesis. In: Becker FF, ed. Cancer: a comprehensive treatise. 2d ed. Vol. 1. New York: Plenum Press. (in press).
  93. Baserga R. The cell cycle. *N Engl J Med*. 1981; 304:453-9.
  94. Berenblum I. Theoretical and practical aspects of the two-stage mechanism of carcinogenesis. In: Griffin AC, Shaw CR, eds. Carcinogen identification and mechanisms of action. New York: Raven Press, 1979:25-34.
  95. Pictet HC, Sirois AE. The stages of initiation and promotion in hepatocarcinogenesis. *Biochim Biophys Acta*. 1980; 605:191-213.
  96. Welch CU, Nagasawa H. Prolactin and murine mammary tumorigenesis: a review. *Cancer Res*. 1977; 37:951-63.
  97. Narisawa T, Magada NE, Weisburger JH, Wynder EL. Promoting effect of bile acids on colon carcinogenesis after intrarectal installation of *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine in rats. *J Natl Cancer Inst*. 1974; 53:1093-7.
  98. Reddy BS, Watanabe K, Weisburger JH, Wynder EL. Promoting effect of bile acids in colon carcinogenesis in germ-free and conventional F344 rats. *Cancer Res*. 1977; 37:3238-42.
  99. Navarrete A, Spjut HJ. Effect of colestyramine on experimentally produced neoplasms of the colon of the rat. *Cancer*. 1967; 20:1466-72.
  100. Gennaro AR, Villanueva R, Sukonthamon Y, Vathanophas V, Rosemond GP. Chemical carcinogenesis in transposed intestinal segments. *Cancer Res*. 1973; 33:536-41.
  101. Oyasu R, Hirao Y, Izumi K. Promotion by urine of urinary bladder carcinogenesis. *Proc Am Assoc Cancer Res Am Soc Clin Oncol*. 1980; 21:70. abstract.
  102. Rowland RG, Henneberry MO, Oyasu R, Orsbyback JT. Effects of urine and continued exposure to carcinogen on progression of early neoplastic urinary bladder lesions. *Cancer Res*. 1980; 40:4524-7.
  103. Farber E. Reversible and irreversible lesions in processes of cancer development. In: Montesano R, Baruch H, Tomatis L, eds. Molecular and cellular aspects of carcinogen screening tests. Lyon: International Agency for Research on Cancer, 1980:143-51. (IARC scientific publications no. 27).
  104. Sporn MB, Newton DL. Chemoprevention of cancer with retinoids. *Fed Proc*. 1979; 38:2528-34.
  105. Shih C, Shilo B-Z, Goldfarb MP, Dannenberg A, Weinberg RA. Passage of phenotypes of chemically transformed cells via transfection of DNA and chromatin. *Proc Natl Acad Sci USA*. 1979; 76:5714-8.
  106. Cooper GM, Okenquist S, Silverman L. Transforming activity of DNA of chemically transformed and normal cells. *Nature*. 1980; 284:418-21.
  107. Armstrong BK. The role of diet in human carcinogenesis with special reference to endometrial cancer. In: Hiatt HH, Watson JD, Winstan JA, eds. Origins of human cancer. Vol. A. New York: Cold Spring Harbor Laboratory, 1977:357-65.
  108. Wynder EL, Reddy BS. Diet and cancer of the colon. In: Winick M, ed. Current concepts in nutrition. New York: John Wiley, 1977; 653-71.
  109. Carroll KK. Lipids and carcinogenesis. *J Environ Pathol Toxicol*. 1980; 3:353-71.
  110. Lijinsky W. Significance of *in vivo* formation of *N*-nitroso compounds. *Oncology*. 1980; 37:223-4.
  111. Mirvab SS. Formation of *N*-nitroso compounds: chemistry, kinetics and *in vivo* occurrence. *Toxicol Appl Pharmacol*. 1975; 31:325-51.
  112. Bruce WR, Eyzers GM, Ciampi A, Dies PW, Boyd N. Strategies for dietary intervention studies in colon cancer. *Cancer*. 1981; 47:1121-5.
  113. Harris CC. A delayed complication of cancer therapy — cancer. *J Natl Cancer Inst*. 1979; 63:275-7.
  114. Hoover R, Fraumeni JF Jr. *Drugs*. 185-98.
  115. Meadows AT, Krymas NL, Belasco JB. The medical cost of cure: sequelae in survivors of childhood cancer. In: van Eys J, Sullivan MP, eds. Status of the curability of childhood cancers. New York: Raven Press, 1980:263-76.
  116. Stich HF, San RHC, eds. Short-term tests for chemical carcinogens. New York: Springer-Verlag, 1981.
  117. Hollstein MJ, McCann J, Angelosante FA, Nichols WW. Short-term test for carcinogens and mutagens. *Mutat Res*. 1979; 65:133-226.
  118. Baruch H, Malaveille C, Camus A-M, et al. Validation and comparative studies on 180 chemicals with *S. typhimurium* strains and V79 Chinese hamster cells in the presence of various metabolizing systems. *Mutat Res*. 1980; 76:1-30.

ST0005480

react to the personnel and work stress. Several characteristics and perceived social support moderated these effects. Job dissatisfaction was found to be an intermediary phase in the development of stress at work. The applied transactional model was found feasible for explaining the relationships between the concepts studied on the basis of the acquired results.

--Condensed from text

363/81 Occupationally Induced Stress, Strain and Peak Loads as Related to Age. J. Ilmarinen and J. Rantanen. *Scand. J. Work Environ. Health* 7: 274-282, Dec. 1980. 25 refs.

From six different types of work 170 men, aged 25-60 y, were classified according to the Ergonomic Job Description Questionnaire into four groups representing specific work content (producing forces, coordinating motor and sensory functions, converting information into reactions, and producing information). Work stress was assessed with measurements of oxygen consumption ( $\dot{V}O_2$ ) and with the registration of the minutes spent at different stress levels. Relative aerobic strain (RAS) was defined as the  $\dot{V}O_2$  during work as the percentage of  $\dot{V}O_{2max}$ . Strain was measured with continuous recordings of heart rate during the workday. Peak loads were calculated according to the relative number of minutes above the heart rate levels of 130, 150 and 170 beats/min. The  $\dot{V}O_2$  during work was virtually identical in the age groups < 35, 35-50 and > 50 y. The RAS tended to increase with age due to the decrease in  $\dot{V}O_{2max}$ . The strain remained practically the same in all the age groups. In the group "coordinating motor and sensory functions" strain tended to increase with age. Peak loads over 150 beats/min were not seen for the older subjects. The results suggest that stress and strain during work remain practically the same as age increases. The RAS, however, tends to increase with age within groups doing mainly physical work and with exposures to peak loads.

--Authors' abstract reprinted by permission

364/81 Ergonomics: The Mechanics of Man 2 -- The Physiology of Work. C. Hayne. *Occup. Med.* 31: 18-24, Jan. 1981. 10 refs.

Fatigue, though better understood today than ever before, is still too complex to be measured by any direct method. When considering the demands of work in relation to energy expenditure and fatigue, it is necessary to be aware of the many elements, both physiological and psychological, associated with human performance. The relation to fatigue may not always be in longer work pauses but in the redesign of activities to produce greater job enrichment and satisfaction.

--Condensed from text

365/81 The Uses and Limits of Standard Exercise Tests. L.B. McGuire. *Arch. Intern. Med.* 141: 229-232, Feb. 1981. 37 refs.

Standard exercise electrocardiography to detect coronary artery disease involves limitations of accuracy in a population of apparently healthy persons, to the extent that its value for counseling such individuals is doubtful. Among subjects being examined for chest pain, however, the accuracy of the exercise ECG in predicting coronary obstructive disease is better. In addition, the presence of more severe coronary obstructive disease tends to be associated with more distinctly abnormal tests at low levels of exercise. This tendency of association between marked ST-segment displacement at low exertion levels and more severe obstructive disease adds a measure of prognostic value to the standard exercise ECG in persons with chest pain or after myocardial infarction. The addition of either isotopic cardiac imaging or coronary arteriography to exercise ECG will be appropriate for situations in which either the ECG is known to be nonspecific or inadequate exercise is achieved.

--Author's abstract reprinted by permission

366/81 Therapeutics of Hypertension in the Work Environment. G.T. McInnes and E.B. Macdonald. *J. Soc. Occup. Med.* 31: 31-37, Jan. 1981. 12 refs.

Essential hypertension is a major health problem among people at work. Current therapy is discussed and the potential role of the occupational health worker explained.

--Authors' summary reprinted by permission

367/81 Relative Importance of Cigarette Smoking in Occupational Lung Disease. P.C. Elmes. *Brit. J. Ind. Med.* 38: 1-13, Feb. 1981. 30 refs.

Since 1900 respiratory disease has remained a constant serious cause of chronic ill health and premature death in Britain. The falling importance of tuberculosis and pneumonia has been off-set by the rise in lung cancer. Bronchitis morbidity and mortality have fallen only slightly since 1935. To produce any real improvement in the future existing information as to cause must be studied. The relative contribution of occupational exposure is compared with the importance of cigarette smoking. Relevant information is scanty and has been produced to emphasize the existence of occupational diseases rather than assess their importance to the community as a whole. In Britain the evidence is that within the coal mining and iron and steel industries conditions are now such that dust exposure contributes little to the morbidity or mortality compared with the workers' smoking habits.